OnCo
ideasIdea

Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route

Putting the CAR gene into T cells without a virus removes the most expensive and delay-prone ingredient. Test whether non-viral products match viral ones.

Transposon systems (piggyBac, Sleeping Beauty) and CRISPR-mediated targeted insertion (for example into the TRAC locus) deliver CAR constructs as DNA or RNA without lentiviral vector, cutting materials cost and removing the vector supply queue; clinical experience exists from Poseida, MD Anderson, Chinese academic groups and others, with an early piggyBac safety signal (lymphoma from integration) in one Australian programme that informs design. The proposal is a head-to-head programme establishing non-viral manufacturing as the default for new autologous and allogeneic CAR-T, with integration-site safety monitoring as a shared standard.

Hypothesis
Non-viral CD19 CAR-T achieves transduction efficiency, persistence and 12-month response rates non-inferior to lentiviral products at a materials cost per dose lower by at least $15,000, with no excess of integration-related malignancy over five years of follow-up.
Rationale
Vector supply is a scheduling and cost bottleneck unrelated to the biology of the product; targeted insertion may also improve product consistency by placing the CAR under endogenous regulation.
What would test it
Randomised phase 2 of non-viral versus lentiviral CD19 CAR-T in relapsed lymphoma with manufacturing cost, vein-to-vein time and integration-site analysis as co-primary manufacturing endpoints.
Maturity
early clinical
Who has to act
research
Cost to try
Medium ($1M to $50M)
Years to first evidence
4
Bottlenecks it attacks

Connected

5top

Pages like this

not linked directly; found by shared links

cancers

1
Diffuse large B-cell lymphoma

technologies

2
Allogeneic (off-the-shelf) cell therapyCAR-T cell therapy

targets

1
CD19

bottlenecks

1
Manufacturing cost and time for living and radioactive medicines